Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

Lancet Diabetes Endocrinol · 2023 · PMC10957483 · PMID 37865101

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

However, this observation is based on a very small number of events, marginally significant tests for heterogeneity or trend, and is not supported by either of the secondary outcomes.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.